Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects
A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the FXR-agonist EYP001a in Chronically HBV Infected Subjects
Sponsor: CPR Pharma Services Pty Ltd, Australia
Listed as NCT03272009, this PHASE1 trial focuses on Hepatitis B, Chronic and remains completed. Sponsored by CPR Pharma Services Pty Ltd, Australia, it has been updated 10 times since 2017, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Aug 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Nov 2017 — Mar 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Nov 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CPR Pharma Services Pty Ltd, Australia
- Enyo Pharma
For direct contact, visit the study record on ClinicalTrials.gov .